DERM PE Ratio & Valuation, Is DERM Overvalued

Historical Valuation

Journey Medical Corp (DERM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 2.16 is considered Overvalued compared with the five-year average of 16.15. The fair price of Journey Medical Corp (DERM) is between 2.98 to 6.29 according to relative valuation method. Compared to the current price of 7.22 USD , Journey Medical Corp By Overvalued By 14.79%.

Relative Value

Fair Zone

2.98-6.29

Current Price：7.22

14.79%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Journey Medical Corp (DERM) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Journey Medical Corp (DERM) has a current Price-to-Book (P/B) ratio of 7.59. Compared to its 3-year average P/B ratio of 752.02, the current P/B ratio is approximately -98.99% higher. Relative to its 5-year average P/B ratio of 508.51, the current P/B ratio is about -98.51% higher. Journey Medical Corp (DERM) has a Forward Free Cash Flow (FCF) yield of approximately -1.94%. Compared to its 3-year average FCF yield of -10.04%, the current FCF yield is approximately -80.62% lower. Relative to its 5-year average FCF yield of -11.18%, the current FCF yield is about -82.60% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for DERM competitors is 1.64, providing a benchmark for relative valuation. Journey Medical Corp Corp (DERM.O) exhibits a P/S ratio of 2.16, which is 31.86% above the industry average. Given its robust revenue growth of 20.52%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of DERM increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of DERM in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is DERM currently overvalued or undervalued?

What is Journey Medical Corp (DERM) fair value?

DERM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Journey Medical Corp (DERM) is between 2.98 to 6.29 according to relative valuation method.

How does DERM's valuation metrics compare to the industry average?

The average P/S ratio for DERM's competitors is 1.64, providing a benchmark for relative valuation. Journey Medical Corp Corp (DERM) exhibits a P/S ratio of 2.16, which is 31.86% above the industry average. Given its robust revenue growth of 20.52%, this premium appears sustainable.

What is the current P/B ratio for Journey Medical Corp (DERM) as of Mar 14 2026?

As of Mar 14 2026, Journey Medical Corp (DERM) has a P/B ratio of 7.59. This indicates that the market values DERM at 7.59 times its book value.

What is the current FCF Yield for Journey Medical Corp (DERM) as of Mar 14 2026?

As of Mar 14 2026, Journey Medical Corp (DERM) has a FCF Yield of -1.94%. This means that for every dollar of Journey Medical Corp's market capitalization, the company generates -1.94 cents in free cash flow.

What is the current Forward P/E ratio for Journey Medical Corp (DERM) as of Mar 14 2026?

As of Mar 14 2026, Journey Medical Corp (DERM) has a Forward P/E ratio of 59.60. This means the market is willing to pay $59.60 for every dollar of Journey Medical Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Journey Medical Corp (DERM) as of Mar 14 2026?

As of Mar 14 2026, Journey Medical Corp (DERM) has a Forward P/S ratio of 2.16. This means the market is valuing DERM at $2.16 for every dollar of expected revenue over the next 12 months.

DERM Valuation